Biologics & Large Molecule Formulations: Injectables, Monoclonal Antibodies, and Peptides

Abstract

Biologics and large molecule therapeutics, including monoclonal antibodies (mAbs), peptides, and other protein-based drugs, have revolutionized modern medicine due to their high specificity and efficacy in treating complex diseases such as cancer, autoimmune disorders, and infectious diseases. Unlike small molecules, biologics pose significant formulation and delivery challenges due to their inherent instability, high molecular weight, and sensitivity to environmental conditions. Injectable formulations remain the primary route of administration, requiring careful design to maintain structural integrity, therapeutic potency, and patient compliance. This review provides an in-depth analysis of biologics and large molecule therapeutics, focusing on injectable formulations, stability considerations, delivery strategies, and regulatory aspects. Advances in formulation technologies, including stabilization with excipients, lyophilization, controlled-release systems, and novel delivery devices, are discussed. Future perspectives emphasize the development of patient-friendly administration methods and innovations in large molecule drug design.

KEYWORDS: Biologics, Monoclonal antibodies, Peptides, Injectable formulations, large molecule therapeutics, Stability, Drug delivery, Lyophilization